{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'study can affect an unborn baby. Women should not', 'breastfeed a baby while on this study. It is important that', 'patients understand the need to use birth control while on', 'this study.', 'Female patients of childbearing potential and fertile male', 'patients must agree to use 2 methods of highly effective', 'contraception (1 highly effective and 1 effective) and have', 'a negative serum pregnancy test at Screening, and male', 'patients must use an effective barrier method of', 'contraception if sexually active with a female of', 'childbearing potential listed below (ie, results in a low', 'failure rate when used consistently and correctly) during', 'the dosing period and for a period of at least 3 months', 'after the end of treatment.', 'Highly effective methods include:', 'Hormonal contraceptives (e.g., combined oral', 'contraceptives, patch, vaginal ring, injectables, and', 'implants)', 'combined (estrogen and progestogen containing)', 'hormonal contraception associated with inhibition', 'of ovulation:', 'oral', 'intravaginal', 'transdermal', 'progestogen-only hormonal contraception', 'associated with inhibition of ovulation:', 'oral', 'injectable', 'implantable', 'tintrauterine device or', 'intrauterine hormone-releasing system', 'Confidential', 'Page 126', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'Vasectomy or tubal ligation', 'bilateral tubal occlusion', 'vasectomized partner', 'sexual abstinence', 'Effective methods include:', 'Barrier methods of contraception (e.g., male condom,', 'female condom, cervical cap, diaphragm, and', 'contraceptive sponge)', 'f particular note,', 'No barrier method by itself achieves a highly effective', 'standard of contraception', 'The proper use of liaphragm or cervical cap includes', 'use of spermicide and is considered t barrier method.', 'The cervical cap and contraceptive sponge are less', 'effective in parous women.', 'The use of spermicide alone is not considered a suitable', 'barrier method for contraception.', 'A combination of male condom with either cap,', 'diaphragm or sponge with spermicide (double barrier', 'methods) are also considered acceptable (i.e., effective),', 'but not highly effective, birth control methods.', 'Male and female condoms should not be used together as', 'they can tear or become damaged.', 'Alternatively, the following fulfill the contraception', 'requirements:', 'Confidential', 'Page 127', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'A sexual partner who is permanently surgically sterilized', 'or post menopausal.', 'Total (true) abstinence (when this is in line with the', 'preferred and usual lifestyle of the patient) is an', 'acceptable method of contraception. Note: Periodic', 'abstinence (e.g., calendar, ovulation, symptothermal, and', 'post-ovulation methods) and withdrawal are not', 'acceptable methods of contraception.', 'The methods of acceptable contraception must be explained to', 'both male and female potential patients. In order to be eligible', 'for the study, patients must agree to use the methods of birth', 'control described above throughout the study and for 3 months', 'following the last dose of study treatment at the time of consent', 'for the study.', 'Please see Section 4.2.7.1 for additional safety', 'information related to pregnancy.', 'Section 12.3.1 Pregnancy and Breastfeeding', 'Note: Pregnancy per se is not considered to be an AE;', 'however, it is discussed here because of the importance of', 'reporting pregnancies that occur during studies and', 'because a medical occurrence observed in the mother or', 'fetus/newborn would be classified as an AE.', 'To ensure patient safety, a pregnancy occurring while the', 'patient is on study treatment must be reported to', 'Karyopharm tharmacovigilance by email or fax within 24', 'hours of first knowledge of its occurrence. A pregnancy', 'report form is provided by Karyopharm.', 'Female patients of childbearing potential and fertile male', 'patients will be informed as to the potential risk of', 'conception while participating in this study and will be', 'advised that they must use highly effective contraception', 'Confidential', 'Page 128', 'Version 4.0']\n\n###\n\n", "completion": "END"}